Boldine inhibits the alveolar bone resorption during ligature-induced periodontitis by modulating the Th17/Treg imbalance
Author
dc.contributor.author
Cafferatta Chea, Emilio
Author
dc.contributor.author
Castro Saavedra, Sebastián
Author
dc.contributor.author
Fuentes Barros, Gonzalo
Author
dc.contributor.author
Melgar Rodríguez, Samanta
Author
dc.contributor.author
Rivera Rodríguez, Felipe
Author
dc.contributor.author
Carvajal Pavez, Paola
Author
dc.contributor.author
Hernández Ríos, Emma
Author
dc.contributor.author
Cortés, Bastián
Author
dc.contributor.author
Cortez, Cristian
Author
dc.contributor.author
Cassels Niven, Bruce
Author
dc.contributor.author
Vernal Astudillo, Rolando
Admission date
dc.date.accessioned
2020-10-19T15:50:50Z
Available date
dc.date.available
2020-10-19T15:50:50Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
J Periodontol. 2020;1–14.
es_ES
Identifier
dc.identifier.other
10.1002/JPER.20-0055
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/177212
Abstract
dc.description.abstract
Background During periodontitis, tooth-supporting alveolar bone is resorbed when there is an increased expression of the pro-osteolytic factor termed receptor activator of nuclear factor kappa B ligand (RANKL), which is responsible for osteoclast differentiation and activation. In periodontitis-affected tissues, the imbalance between T-helper type-17 (Th17) and T-regulatory (Treg) lymphocyte activity favors this RANKL overexpression. In this context, immunotherapeutic strategies aimed at modulating this Th17/Treg imbalance could eventually arrest the RANKL-mediated alveolar bone loss. Boldine has been reported to protect from pathological bone loss during rheumatoid arthritis and osteoporosis, whose pathogenesis is associated with a Th17/Treg imbalance. However, the effect of boldine on alveolar bone resorption during periodontitis has not been elucidated yet. This study aimed to determine whether boldine inhibits alveolar bone resorption by modulating the Th17/Treg imbalance during periodontitis. Methods Mice with ligature-induced periodontitis were orally treated with boldine (10/20/40 mg/kg) for 15 consecutive days. Non-treated periodontitis-affected mice and non-ligated mice were used as controls. Alveolar bone loss was analyzed by micro-computed tomography and scanning electron microscopy. Osteoclasts were quantified by histological identification of tartrate-resistant acid phosphatase-positive cells. Production of RANKL and its competitive antagonist osteoprotegerin (OPG) were analyzed by ELISA, quantitative polymerase chain reaction (qPCR), and immunohistochemistry. The Th17 and Treg responses were analyzed by quantifying the T-cell frequency and number by flow cytometry. Also, the expression of their signature transcription factors and cytokines were quantified by qPCR. Results Boldine inhibited the alveolar bone resorption. Consistently, boldine caused a decrease in the osteoclast number and RANKL/OPG ratio in periodontal lesions. Besides, boldine reduced the Th17-lymphocyte detection and response and increased the Treg-lymphocyte detection and response in periodontitis-affected tissues. Conclusion Boldine, administered orally, inhibited the alveolar bone resorption and modulated the Th17/Treg imbalance during experimental periodontitis.
es_ES
Patrocinador
dc.description.sponsorship
Plataforma Experimental Bio-CT (FONDEQUIP, Faculty of Dentistry, Universidad de Chile)
EQM150010
FONDECYT from the Chilean Governmental Agencia Nacional de Investigacion y Desarrollo (ANID)
1181780
Graduate School of the Faculty of Dentistry, Universidad de Chile
ANID
21192219